Celgene Stock Price, News & Analysis (NASDAQ:CELG)

$95.26 -0.88 (-0.92 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$95.26
Today's Range$95.24 - $96.80
52-Week Range$88.32 - $147.17
Volume5.75 million shs
Average Volume8.58 million shs
Market Capitalization$71 billion
P/E Ratio18.14
Dividend YieldN/A
Beta1.49

About Celgene (NASDAQ:CELG)

Celgene logoCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:CELG
CUSIP15102010
Phone+1-908-6739000

Debt

Debt-to-Equity Ratio2.29%
Current Ratio4.99%
Quick Ratio4.80%

Price-To-Earnings

Trailing P/E Ratio18.1447619047619
Forward P/E Ratio12.40
P/E Growth0.68

Sales & Book Value

Annual Sales$13.00 billion
Price / Sales5.51
Cash Flow$7.55 per share
Price / Cash12.62
Book Value$9.20 per share
Price / Book10.35

Profitability

Trailing EPS$5.25
Net Income$2.94 billion
Net Margins22.38%
Return on Equity67.50%
Return on Assets18.33%

Miscellaneous

Employees7,467
Outstanding Shares752,180,000

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Celgene shares split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene announced that its Board of Directors has initiated a share repurchase program on Wednesday, February 14th 2018, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board of directors believes its stock is undervalued.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) issued its quarterly earnings results on Thursday, January, 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.78 by $0.09. The biopharmaceutical company had revenue of $3.48 billion for the quarter, compared to analysts' expectations of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The firm's quarterly revenue was up 16.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.61 earnings per share. View Celgene's Earnings History.

When will Celgene make its next earnings announcement?

Celgene is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene issued an update on its FY18 earnings guidance on Thursday, January, 25th. The company provided earnings per share (EPS) guidance of $8.70-8.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.65. The company issued revenue guidance of $14.4-14.8 billion, compared to the consensus revenue estimate of $14.77 billion.

Where is Celgene's stock going? Where will Celgene's stock price be in 2018?

30 analysts have issued 1-year price targets for Celgene's stock. Their forecasts range from $91.00 to $166.00. On average, they expect Celgene's share price to reach $130.36 in the next twelve months. View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:

  • 1. Cann analysts commented, "Celgene announced today that John Weiland has been elected to its board of directors. Mr. Weiland was most recently President and Chief Operating Officer of C.R. Bard, Inc. Prior to this role, Mr. Weiland held the position of Group President of Bard and had global responsibility for Bard Medical Division, Bard Urological Division, Davol Inc., Bard Endoscopic Technologies Division and Bard’s Worldwide Manufacturing Operations. We believe Mr. Weiland will bring significant commercial and operational experience to the Celgene Board." (2/15/2018)
  • 2. According to Zacks Investment Research, "Celgene’s fourth-quarter results were encouraging as the company beat on both sales and earnings. While Revlimid sales were impressive yet again, Abraxane sales declined in the United States. Sales of Otezla have picked up too after a slowdown in the third quarter. However, Celgene is highly dependent on Revlimid. Celgene’s stock has underperformed the industry in the last six months. Celgene suffered a setback as the label expansion study on lead drug Revlimid failed in phase III. The stock was hit earlier after a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn’s disease and the extension trial, SUSTAIN (CD-004) was discontinued.  The threat of generic competition is also looming large on Revlimid forcing Celgene to look for acquisitions and the announcement of Juno’s acquisition was on the same track. However, the Juno acquisition comes with its own set of risks." (1/31/2018)
  • 3. Cantor Fitzgerald analysts commented, "CELG’s current CEO, Mark Alles, will assume the role of Chairman of the Board, following the retirement of current COB Robert Hugin, effective February 5th, which follows his departure as President in early 2016." (1/29/2018)

Are investors shorting Celgene?

Celgene saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 14,380,412 shares, an increase of 10.3% from the January 12th total of 13,038,301 shares. Based on an average daily trading volume, of 9,042,197 shares, the short-interest ratio is presently 1.6 days. Approximately 1.8% of the company's stock are short sold.

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:

  • Mark J. Alles, Chairman of the Board, Chief Executive Officer (Age 58)
  • Scott A. Smith, President, Chief Operating Officer (Age 55)
  • Peter N. Kellogg, Chief Financial Officer, Executive Vice President (Age 61)
  • Terrie Curran, President, Global Inflammation & Immunology Franchise (Age 48)
  • Michael F. Pehl, President, Hematology & Oncology (Age 52)
  • Rupert J Vessey, President - Research and Early Development (Age 52)
  • Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary (Age 49)
  • Michael D. Casey, Lead Independent Director (Age 71)
  • Michael W. Bonney, Director (Age 59)
  • Julia A. Haller M.D., Director (Age 62)

Who owns Celgene stock?

Celgene's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.26%), Franklin Resources Inc. (1.38%), Jennison Associates LLC (1.25%), Bank of New York Mellon Corp (1.17%), Geode Capital Management LLC (1.10%) and Clearbridge Investments LLC (0.84%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Mark J Alles, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Who sold Celgene stock? Who is selling Celgene stock?

Celgene's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Standard Life Aberdeen plc, American Century Companies Inc., UBS Asset Management Americas Inc., Amundi Pioneer Asset Management Inc., First American Bank, Fred Alger Management Inc. and Lazard Asset Management LLC. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Insider Buying and Selling for Celgene.

Who bought Celgene stock? Who is buying Celgene stock?

Celgene's stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, HealthCor Management L.P., Clearbridge Investments LLC, Arrowstreet Capital Limited Partnership, Two Sigma Investments LP, Redmile Group LLC, Swedbank and Thrivent Financial For Lutherans. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene, Mark J Alles and Michael W Bonney. View Insider Buying and Selling for Celgene.

How do I buy Celgene stock?

Shares of Celgene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of Celgene stock can currently be purchased for approximately $95.26.

How big of a company is Celgene?

Celgene has a market capitalization of $71 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $5.25 on an earnings per share basis. Celgene employs 7,467 workers across the globe.

How can I contact Celgene?

Celgene's mailing address is 86 Morris Ave, SUMMIT, NJ 07901-3915, United States. The biopharmaceutical company can be reached via phone at +1-908-6739000 or via email at [email protected]


MarketBeat Community Rating for Celgene (CELG)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  1,709 (Thanks for Voting!)
Underperform Votes:  513 (Thanks for Voting!)
Total Votes:  2,222
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celgene (NASDAQ:CELG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.532.662.77
Ratings Breakdown: 1 Sell Rating(s)
11 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
12 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
18 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $130.36$130.14$140.03$147.58
Price Target Upside: 38.11% upside27.94% upside34.51% upside9.10% upside

Celgene (NASDAQ:CELG) Consensus Price Target History

Price Target History for Celgene (NASDAQ:CELG)

Celgene (NASDAQ:CELG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018CannReiterated RatingBuy$163.00LowView Rating Details
2/13/2018BarclaysUpgradeEqual Weight -> Overweight$91.51 -> $105.00LowView Rating Details
2/4/2018MizuhoReiterated RatingBuy$128.00HighView Rating Details
1/29/2018Cantor FitzgeraldReiterated RatingHold$112.00MediumView Rating Details
1/26/2018SunTrust BanksReiterated RatingBuy$127.00 -> $139.00LowView Rating Details
1/24/2018BMO Capital MarketsReiterated RatingBuy$144.00LowView Rating Details
1/23/2018Royal Bank of CanadaReiterated RatingTop PickLowView Rating Details
1/23/2018BTIG ResearchReiterated RatingHoldMediumView Rating Details
1/18/2018Piper Jaffray CompaniesReiterated RatingHold$104.00LowView Rating Details
1/10/2018GuggenheimReiterated RatingBuy$147.00LowView Rating Details
1/8/2018Credit Suisse GroupSet Price TargetBuy$125.00MediumView Rating Details
1/8/2018Stifel NicolausSet Price TargetBuy$130.00MediumView Rating Details
1/8/2018Deutsche BankSet Price TargetHold$110.00LowView Rating Details
1/8/2018OppenheimerSet Price TargetBuy$166.00HighView Rating Details
1/5/2018Bank of AmericaDowngradeBuy -> Neutral$104.68 -> $120.00MediumView Rating Details
12/27/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$121.00HighView Rating Details
12/22/2017Leerink SwannReiterated RatingBuy$120.00LowView Rating Details
12/22/2017CitigroupReiterated RatingHoldMediumView Rating Details
12/8/2017Atlantic SecuritiesUpgradeNeutral -> OverweightHighView Rating Details
11/16/2017Canaccord GenuitySet Price TargetBuy$140.00N/AView Rating Details
10/27/2017JPMorgan Chase & Co.Set Price TargetBuy$123.00N/AView Rating Details
10/27/2017Goldman Sachs GroupReiterated RatingSell$116.00 -> $91.00N/AView Rating Details
10/27/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
10/27/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
10/27/2017Robert W. BairdReiterated RatingHold$103.00N/AView Rating Details
10/26/2017Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
10/20/2017William BlairReiterated RatingOutperformN/AView Rating Details
10/16/2017Jefferies GroupReiterated RatingBuy$160.00N/AView Rating Details
9/12/2017CowenReiterated RatingBuy$150.00LowView Rating Details
7/31/2017ArgusUpgradeHold -> Buy$96.93 -> $160.00LowView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
4/28/2016Raymond James FinancialReiterated RatingBuyN/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Celgene (NASDAQ:CELG) Earnings History and Estimates Chart

Earnings by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ CELG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018$1.96N/AView Earnings Details
1/25/2018Q4 2017$1.78$1.87$3.46 billion$3.48 billionViewListenView Earnings Details
10/26/2017Q3 2017$1.87$1.91$3.42 billion$3.29 billionViewN/AView Earnings Details
7/27/20176/30/2017$1.61$1.82$3.23 billion$3.27 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.47$1.68$3.04 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
10/28/2010Q3 2010$0.32$0.32ViewN/AView Earnings Details
7/29/2010Q2 2010$0.30$0.30ViewN/AView Earnings Details
4/29/2010Q1 2010$0.28$0.27ViewN/AView Earnings Details
1/28/2010Q4 2009$0.29$0.29ViewN/AView Earnings Details
10/22/2009Q3 2009$0.25$0.25ViewN/AView Earnings Details
7/23/2009Q2 2009$0.21$0.20ViewN/AView Earnings Details
4/30/2009Q1 2009$0.20$0.16ViewN/AView Earnings Details
1/29/2009Q4 2008$0.19$0.19ViewN/AView Earnings Details
10/23/2008Q3 2008$0.18$0.17ViewN/AView Earnings Details
7/24/2008Q2 2008$0.16$0.15ViewN/AView Earnings Details
5/8/2008Q1 2008$0.16$0.17ViewN/AView Earnings Details
1/31/2008Q4 2007$0.15$0.15ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Celgene (NASDAQ:CELG) Earnings Estimates

2018 EPS Consensus Estimate: $7.93
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.83$1.83$1.83
Q2 20181$1.94$1.94$1.94
Q3 20181$2.00$2.00$2.00
Q4 20181$2.16$2.16$2.16
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Celgene (NASDAQ:CELG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Celgene (NASDAQ CELG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 78.10%
Insider Trades by Quarter for Celgene (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ CELG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2018Mark J AllesInsiderBuy3,260$91.90$299,594.00178,904View SEC Filing  
9/25/2017Terrie CurranInsiderSell1,727$143.89$248,498.033,925View SEC Filing  
9/12/2017Gilla KaplanDirectorSell9,250$141.56$1,309,430.0085,551View SEC Filing  
9/5/2017Michael D CaseyDirectorSell9,250$139.03$1,286,027.509,250View SEC Filing  
8/10/2017Ernest MarioDirectorSell18,506$130.52$2,415,403.1269,424View SEC Filing  
8/2/2017Gilla KaplanDirectorSell7,500$134.52$1,008,900.0076,301View SEC Filing  
6/26/2017James J LoughlinDirectorSell18,500$133.57$2,471,045.0032,877View SEC Filing  
6/22/2017Michael A FriedmanDirectorSell10,000$132.50$1,325,000.005,000View SEC Filing  
6/22/2017Robert J HuginInsiderSell175,970$134.14$23,604,615.801,033,909View SEC Filing  
6/21/2017Michael D CaseyDirectorSell9,250$133.05$1,230,712.509,250View SEC Filing  
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.304,004View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.0032,169View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.3973,109View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00778View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.0018,600View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.5650,000View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.0031,332View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.4072,142View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.0042,919View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.001,022,201View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.001,122,201View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.2872,518View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.0019,785View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.0082,449View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.6888,485View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.0088,485View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.1625,705View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00100,671View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.7850View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.0022,688View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.7815,349View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celgene (NASDAQ CELG) News Headlines

Source:
DateHeadline
Global Cutaneous T-Cell Lymphoma (CTCL) Market Spotlight 2017: Celgene Leads Industry Sponsors with the Highest ... - PR Newswire (press release)Global Cutaneous T-Cell Lymphoma (CTCL) Market Spotlight 2017: Celgene Leads Industry Sponsors with the Highest ... - PR Newswire (press release)
www.prnewswire.com - February 16 at 3:44 PM
What You Must Know About Celgene Corporation’s (NASDAQ:CELG) ROEWhat You Must Know About Celgene Corporation’s (NASDAQ:CELG) ROE
finance.yahoo.com - February 16 at 3:44 PM
At $96.14, Celgene (CELG) a SellAt $96.14, Celgene (CELG) a Sell
investorplace.com - February 16 at 12:42 PM
Worldwide Cancer Immunotherapy Market is expected to grow at a healthy CAGR of 14.8% and reach till USD 101.6 billion by 2023Worldwide Cancer Immunotherapy Market is expected to grow at a healthy CAGR of 14.8% and reach till USD 101.6 billion by 2023
www.marketwatch.com - February 16 at 9:54 AM
Billionaire Ray Dalios Bridgewater Bets Big on ETFs: 13F FilingBillionaire Ray Dalio's Bridgewater Bets Big on ETFs: 13F Filing
finance.yahoo.com - February 16 at 9:54 AM
5 Things You Need to Know About Celgene's Future5 Things You Need to Know About Celgene's Future
finance.yahoo.com - February 16 at 9:54 AM
5 Things You Need to Know About Celgenes Future5 Things You Need to Know About Celgene's Future
www.fool.com - February 16 at 8:01 AM
A startup that wants to use stem cells to keep us living longer just raised $250 millionA startup that wants to use stem cells to keep us living longer just raised $250 million
www.businessinsider.com - February 15 at 3:45 PM
Drugmaker CEO turned Senate hopeful: I met with Jamie Dimon on health care and like what he's doingDrugmaker CEO turned Senate hopeful: I met with Jamie Dimon on health care and like what he's doing
finance.yahoo.com - February 15 at 3:45 PM
Celularity raises $250M to develop cell therapies: CEOCelularity raises $250M to develop cell therapies: CEO
finance.yahoo.com - February 15 at 3:45 PM
[$$] Biotech Startup Celularity Launches With $250 Million[$$] Biotech Startup Celularity Launches With $250 Million
finance.yahoo.com - February 15 at 3:45 PM
Celgene Corporation Elects John Weiland to Its Board of DirectorsCelgene Corporation Elects John Weiland to Its Board of Directors
finance.yahoo.com - February 15 at 3:45 PM
Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional RegenerationCelularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration
finance.yahoo.com - February 15 at 3:45 PM
OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative ColitisOTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
finance.yahoo.com - February 15 at 3:45 PM
Celgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack CancerCelgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack Cancer
finance.yahoo.com - February 15 at 3:45 PM
[$$] Buying AMD, Intel, Union Pacific, Selling Wells Fargo[$$] Buying AMD, Intel, Union Pacific, Selling Wells Fargo
finance.yahoo.com - February 15 at 3:45 PM
Cann Reaffirms Buy Rating for Celgene (CELG)Cann Reaffirms Buy Rating for Celgene (CELG)
www.americanbankingnews.com - February 15 at 12:32 PM
Agios Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)Agios Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - February 14 at 3:19 PM
Celgene (CELG) to Buyback $5.00 billion in  Outstanding SharesCelgene (CELG) to Buyback $5.00 billion in Outstanding Shares
www.americanbankingnews.com - February 14 at 11:12 AM
Celgenes Future Growth Could Depend on a Competitors Trial This QuarterCelgene's Future Growth Could Depend on a Competitor's Trial This Quarter
www.fool.com - February 14 at 9:11 AM
Drugmaker CEO turned Senate hopeful: I met with Jamie Dimon on health care and like what hes doingDrugmaker CEO turned Senate hopeful: I met with Jamie Dimon on health care and like what he's doing
www.cnbc.com - February 14 at 9:11 AM
How we can fix our broken health-care system: Former Celgene chiefHow we can fix our broken health-care system: Former Celgene chief
www.cnbc.com - February 14 at 7:15 AM
Former pharma executive and Chris Christie supporter seeks to oust Menendez in NJ Senate primaryFormer pharma executive and Chris Christie supporter seeks to oust Menendez in NJ Senate primary
www.cnbc.com - February 12 at 5:08 PM
Today’s Research Reports on Trending Tickers: Amgen and CelgeneToday’s Research Reports on Trending Tickers: Amgen and Celgene
finance.yahoo.com - February 12 at 3:17 PM
See what the IHS Markit Score report has to say about Celgene Corp.See what the IHS Markit Score report has to say about Celgene Corp.
finance.yahoo.com - February 12 at 3:17 PM
Former Celgene CEO Will Run for New Jersey Senate SeatFormer Celgene CEO Will Run for New Jersey Senate Seat
finance.yahoo.com - February 12 at 3:17 PM
Analyst Recommendations for Amgen in February 2018Analyst Recommendations for Amgen in February 2018
finance.yahoo.com - February 12 at 3:17 PM
Better Buy: Amgen Inc. vs. CelgeneBetter Buy: Amgen Inc. vs. Celgene
www.fool.com - February 11 at 10:35 AM
Celgene Co. (CELG) Short Interest UpdateCelgene Co. (CELG) Short Interest Update
www.americanbankingnews.com - February 9 at 4:58 PM
Celgene Prices $4.5 Billion of Senior Unsecured NotesCelgene Prices $4.5 Billion of Senior Unsecured Notes
finance.yahoo.com - February 9 at 3:24 PM
Stock Market Drop Not Seen Dampening Healthcare Deal Activity - TheStreet.comStock Market Drop Not Seen Dampening Healthcare Deal Activity - TheStreet.com
www.thestreet.com - February 9 at 5:40 AM
Insider Buying: Celgene Co. (CELG) Insider Acquires 3,260 Shares of StockInsider Buying: Celgene Co. (CELG) Insider Acquires 3,260 Shares of Stock
www.americanbankingnews.com - February 8 at 6:32 PM
How Amgen Performed in 4Q17How Amgen Performed in 4Q17
finance.yahoo.com - February 8 at 3:18 PM
Performance of Amgen’s Kyprolis in 2017Performance of Amgen’s Kyprolis in 2017
finance.yahoo.com - February 8 at 3:18 PM
Celgene Corporation -- Moodys rates Celgenes notes Baa2; stable outlookCelgene Corporation -- Moody's rates Celgene's notes Baa2; stable outlook
finance.yahoo.com - February 8 at 3:18 PM
Sanofi Leads the Hemophilia Space on Bioverativ AcquisitionSanofi Leads the Hemophilia Space on Bioverativ Acquisition
finance.yahoo.com - February 8 at 5:27 AM
Celgene Co. (CELG) Receives Average Rating of "Buy" from AnalystsCelgene Co. (CELG) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 6 at 3:48 PM
These Biotechs Could Spring Back After Market Correction: AnalystThese Biotechs Could Spring Back After Market Correction: Analyst
finance.yahoo.com - February 6 at 3:18 PM
Heres Why BeiGene, Ltd. Jumped 38.9% in JanuaryHere's Why BeiGene, Ltd. Jumped 38.9% in January
www.fool.com - February 5 at 4:46 PM
Why Juno Therapeutics Stock Screamed Higher in JanuaryWhy Juno Therapeutics Stock Screamed Higher in January
www.fool.com - February 5 at 8:37 AM
Mizuho Reiterates "Buy" Rating for Celgene (CELG)Mizuho Reiterates "Buy" Rating for Celgene (CELG)
www.americanbankingnews.com - February 5 at 12:28 AM
$3.50 Billion in Sales Expected for Celgene Co. (CELG) This Quarter$3.50 Billion in Sales Expected for Celgene Co. (CELG) This Quarter
www.americanbankingnews.com - February 4 at 6:48 AM
Financial Contrast: Aquinox Pharmaceuticals (AQXP) vs. Celgene (CELG)Financial Contrast: Aquinox Pharmaceuticals (AQXP) vs. Celgene (CELG)
www.americanbankingnews.com - February 4 at 3:18 AM
ACT NOW: Monteverde & Associates PC Investigates the Tender Offer of Juno Therapeutics, Inc. – JUNOACT NOW: Monteverde & Associates PC Investigates the Tender Offer of Juno Therapeutics, Inc. – JUNO
finance.yahoo.com - February 3 at 5:39 AM
GlaxoSmithKline Is Focused on Developing Oncology Asset GSK 916GlaxoSmithKline Is Focused on Developing Oncology Asset GSK 916
finance.yahoo.com - February 2 at 3:18 PM
Celgene Works toward Cell Therapy for Multiple MyelomaCelgene Works toward Cell Therapy for Multiple Myeloma
finance.yahoo.com - February 2 at 3:18 PM
Biogen: How It Performed in 4Q17Biogen: How It Performed in 4Q17
finance.yahoo.com - February 2 at 3:18 PM
Celgene commences tender offer for Juno sharesCelgene commences tender offer for Juno shares
seekingalpha.com - February 2 at 8:40 AM
GRAPHIC-Biotech M&A explodes with $27.5 bln of January dealsGRAPHIC-Biotech M&A explodes with $27.5 bln of January deals
finance.yahoo.com - January 31 at 3:17 PM
Where Atara Biotherapeutics Stands This January: Analyst RatingsWhere Atara Biotherapeutics Stands This January: Analyst Ratings
finance.yahoo.com - January 31 at 3:17 PM

SEC Filings

Celgene (NASDAQ:CELG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celgene (NASDAQ:CELG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celgene (NASDAQ CELG) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.